(BTCY) Rides Huge News Into Today's Opening Bell, Currently Up Approximately 16%

BTCY is humming early and for good reason. (BTCY) Rides Huge News Into Today's Opening Bell, Currently Up Approximately 16% January 26th Dear Reader, BTCY is humming early and for good reason. Up approximately 16%, BTCY has already hit a high of $.88. It could just be the start for BTCY after dropping this incredible news. Check it out: Biotricity Signs Distribution Agreement With Top 5 Distributor for its Cardiac Monitoring Solutions REDWOOD CITY, CA / ACCESSWIRE / January 26, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced it has signed its second distribution agreement with a top five US medical device distributor for the marketing and distribution of its two cardiac monitoring solutions (CMS) designed for cardiologists' patient use - Bioflux® and BiotresTM. The distribution agreement covers Bioflux and Biotres and will be distributed directly to hospitals and clinics for professional medical utilization with suitable patients. Commenting on the agreement, Biotricity Founder, Chairman and CEO Waqaas Al-Siddiq, Ph.D., said, "The future of healthcare lies with new, state-of-the-art technology that produces a more efficient and higher quality of care through remote care. That means tech that is specially designed for smart remote monitoring of individuals using digital/wireless and cloud-based technology with seamless integration with all platforms and devices." "Our Bioflux and Biotres solutions address a market valued at $6Bn, and we fully expect to capture an increasing share of this growing marketplace," Dr. Al-Siddiq added. "We are delivering cardiac care remotely, 24/7 and in real-time as needed, with technology that rivals existing standard of care solutions. Long term, we are confident our technology, and the lifestyle improvements it encourages will bend the curve of growing rates of heart disease." [Read the full article here.]( On top of the news, BTCY is trading above [several lines]( of potential support including its: - 20-Day Simple Moving Average (SMA) - 50-Day SMA - 5-Day Exponential Moving Average (EMA) - 13-Day EMA If potential support continues to grow at those levels, it could become the foundation for BTCY to try and run down previous highs. Take a moment now to read my initial BTCY report below and get this past champ pulled up quickly. ----- It's time to bring your attention back to a Nasdaq past champ. This is an innovative biomedical company leading the way in the development of cutting-edge cardiology care. By leveraging the latest technology and groundbreaking research, they are set to revolutionize the healthcare industry, providing advanced treatments and therapies that are more accessible and affordable. Through the use of advanced diagnostics, personalized treatments, and the utilization of big data, they are set to provide an entirely new level of care for those with cardiac conditions. Taking this into account, I've brought this profile to your attention on multiple occasions and on multiple occasions it has popped-off. I'm talking $1.00+ moves (approx.) after flashing a spotlight on it. So, when you add in a [$7.50 analyst price target]( providing over 700% potential upside, a low float, a new distro agreement with a top GPO, and a product making an important TIME Magazine list, this breakout idea needs to be back at the top of your watch-list. For Thursday, January 26th, there is only one Nasdaq profile to get on your radar: *Biotricity, Inc. (BTCY)* Biotricity is transforming the healthcare market by bridging the gap in remote monitoring and chronic care management with a focus on cardiology. Physicians and patients trust Biotricity's unparalleled standard for preventive and personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. And right now, BTCY has several potential catalysts that could provide it with a near term breakout spark. Check them out: No. 1 - Zacks Small-Cap Research Provides $7.50 Price Target No. 2 - 2023 Sales Could Grow Significantly With Signing Of New Distribution Agreement No. 3 - A Massive Revenue Growth Announcement Highlights A Company On The Rise No. 4 - A Low Float Provides Volatility Potential On A Daily Basis No. 5 - Company's Device Added To Prestigious TIME Magazine List But more on those in a second... Cardiac Market Opp. As of 2018, approximately [30M Americans]( have received a diagnosis. Physicians need an integrated approach, within their practice, that allows them to diagnose and prescribe monitoring equipment to patients with multiple comorbidities. Physicians need to actively monitor data from compromised patients to trigger real-time intervention, reduce patient risk and physician liability through faster diagnosis. Problem: Cardiac Care Cardiac Care is disjointed with different solutions from different vendors. Cardiac issues are intermittent, and patients are often asymptomatic, requiring long-term data with connectivity. Most solutions are passive, i.e. not real time recording devices. Post procedure patients and high-risk patients should remain under observation with real-time RPM. Lack cross compatibility with other devices/solutions. Long-term, continuous monitoring results in better detection of early warning signs in an illness, decreasing [hospital admission rates.]( [Effective use of RPM]( allows physicians to see more patients, perform more procedures, and identify which patients need more time and attention. [(Source)]( Solution: Biosphere Bioflux® Disruptive Business Model - Insourced business model, enabling physicians to bill directly - Minimal upfront cost for physician, physician pays only when device is used – top line pro-fit - Turn-key solution for physicians - Recurring revenue with high margin for Biotricity - Reads are ins. reimbursable using existing CPT billing codes Disruptive Technology - Turn-key solution: device, software, and monitoring center - One piece device that is the smallest in the market - Built-in global GPS and GSM platform Bioflux® MCT Solution Current Footprint - Bioflux® Portfolio of complementary technologies: - Biotres ® - FDA cleared - Bioheart ® - consumer product currently in initial production - Biocare® App – about to go through field testing - Bioflux® 2 – in alpha prototyping Large Scale production in place. Medicare Reimbursement in place. Cardiologists across 29 states use the Bioflux daily. Currently have over 500 centers across 29 states: focused on expanding salesforce to expand footprint. Our sales force is comprised of seasoned professionals, each with a proven track record of introducing disruptive cardiovascular technologies to the marketplace. Use a proprietary data tool to identify target markets within the US, based on CMS reimbursement data. [More Key Details From The Company Presentation.]( ----- And as I mentioned above, BTCY has 5 potential catalysts that could provide it with a breakout spark. Here they are: No. 1 BTCY Potential Catalyst - Zacks Small-Cap Research Provides $7.50 Price Target In 2022, BTCY was tagged with a strong target from [Zacks Small-Cap Research]( that is providing this profile with over 700% potential upside from Wednesday's closing valuation. Here's some key details from the report: Valuation We are optimistic about the outlook for BTCY’s technology and ecosystem as the company expands both distribution and its product and service offerings. At this early stage in its development, it is difficult to compare BTCY to other companies on traditional valuation metrics such as P/E or EV/ EBITDA, in our view. We therefore value BTCY shares using a peer comparables valuation methodology based on EV/Sales. We appreciate the company’s runway and addressable market for additional penetration of its network for Bioflux, the Biotres launch contribution and the recurring revenues stream and shift in the sales mix towards higher margin TaaS over time. We therefore think the current share price level does not reflect the fundamental value of the company’s prospects. As the company continues to advance its strategy, we would anticipate multiple and share price expansion. We believe accelerating revenue ramp as both Bioflux and Biotres gain traction could be catalysts. Although the revenue arc for BTCY is somewhat unclear at this stage because of many variables, including whether the pandemic has a lingering impact and global logistics challenges, we believe it reasonable to project that BTCY can attain revenue in the $40-$45Mn range by FY25-FY26. We reach $7.50 valuation per share based on peer group median of 9.0x EV/sales applied to this anticipated range, which includes a ramp-up in contribution from Biotres, Bioflux and other offerings in development. ----- No. 2 BTCY Potential Catalyst - 2023 Sales Could Grow Significantly With Signing Of New Distribution Agreement Biotricity Signs with Top 5 Group Purchasing Organization; Potential for Higher Sales Volume in 2023 REDWOOD CITY, CA / ACCESSWIRE / January 17, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, announced it has signed an agreement with a leading group ‎purchasing organization ("GPO") for national distribution of its cardiac monitoring solutions, Bioflux® and BiotresTM. Both Bioflux and Biotres are designed for cardiologists to diagnose and monitor their patients remotely. GPO's are entities comprised of businesses organized to purchase materials or supplies from vendors in larger volumes to gain efficiency. In this case, the GPO is comprised of hundreds of small, independent US hospitals, private ‎clinics, and medical offices that purchase medical devices and supplies at scale. "Becoming a newly featured vendor of state-of-the-art cardiac monitoring solutions with a leading medical device & supplies GPO, will boost our visibility industry-wide," said Waqaas Al-Siddiq, Ph.D., Biotricity Founder, Chairman and CEO. "We anticipate increasing revenue growth across 2023 through the expansion of our products' availability through these new sales channels." [Read the full article here.]( ----- No. 3 BTCY Potential Catalyst - A Massive Revenue Growth Announcement Highlights A Company On The Rise Biotricity Surpasses $10Mn in Annual Revenue Run Rate Company Delivers Revenue Growth in 9 Out of the last 10 Consecutive Quarters REDWOOD CITY, CA / ACCESSWIRE / November 21, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced it has surpassed $10Mn in annual revenue run rate. "With strong revenue growth each quarter, our scale and market reach increases every day," says Biotricity Founder and CEO, Dr. Waqaas Al-Siddiq. "I am committed to continuing to drive growth and realize our potential. Our focus remains on providing the cardiac health market with disruptive, superior digital and AI technology at competitive pricing with unrivaled support to our customers and physician partnerships." Biotricity boasts multiple ground-breaking products including Bioflux®, Biotres, and Bioheart which won TIME's Best Inventions of 2022. - Bioflux: a high-precision, single-unit mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of your ECG information to your doctor - Biotres: an easy to wear, rechargeable device with wireless capability, utilizing the advanced technology of the Bioflux® for more active days - Bioheart: a consumer-targeted continuous heart rhythm monitor that uses the most advanced heart technology to deliver unlimited heart data insights with three views of your heart The record revenue run rate is Biotricity's latest achievement in a string of major milestones that include: - The Company's Bioheart personal cardiac monitor won TIME's Best Inventions of 2022 - Awarded $250K NIH grant from the National Heart, Blood, and Lung Institute for AI-enabled real-time monitoring and predictive analytics for stroke due to chronic kidney failure - Surpassed 2 billion recorded and analyzed heartbeats for atrial fibrillation (A-fib) - Company has delivered revenue growth in nine out of the last ten consecutive quarters [Read the full article here.]( ----- No. 4 BTCY Potential Catalyst - A Low Float Provides Volatility Potential On A Daily Basis According to the [Yahoo Finance]( website, BTCY has a relatively low float. The website reports this profile to have approximately 38.92Mn shares in its float. Why is that important? It's important on one crucial level. Volatility. Could positive company news early in 2023 provide a near term spark? ----- No. 5 BTCY Potential Catalyst - Company's Device Added To Prestigious TIME Magazine List Biotricity's Bioheart Named to TIME's List of The Best Inventions of 2022 Bioheart provides consumers the most advanced personal heart monitoring technology, combining powerful analytics and continuous heart monitoring for personalized heart insights REDWOOD CITY, CA / ACCESSWIRE / November 10, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced that its Bioheart device has been named to TIME's list of the Best Inventions of 2022. Bioheart is the first of its kind - a continuous heart rhythm monitor using advanced technology to deliver unlimited heart data insights. Cardiac issues are intermittent, often asymptomatic, and lifelong in nature, requiring continuous heart activity monitoring. Fitness trackers simply collect your heart rate and personal ECG devices manually collect a few minutes of data, leaving you without the full picture. Bioheart changes everything by creating the first heart activity monitor. Whether you are sleeping, sitting, or out exploring the world, Bioheart's uninterrupted monitoring keeps you informed about your heart 24/7. TIME reveals its annual list of the Best Inventions, which features 200 extraordinary innovations changing our lives: time.com/best-inventions-2022. To compile the list, TIME solicited nominations from TIME's editors and correspondents around the world, as well as through an online application process, paying special attention to growing fields-such as the electric vehicle industry, green energy, and the metaverse. TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact. Of the New Best Inventions list, TIME's editors wrote: "The result is a list of 200 groundbreaking inventions (and 50 special mention inventions)- including life-mapping artificial intelligence, diamonds made from excess carbon in the air, and the most powerful telescope ever-that are changing how we live, work, play, and think about what's possible." "We are honored and excited to have our premier consumer product, Bioheart, included in TIME's 2022 list," commented Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity. "Our mission is to disrupt and transform the state of cardiac health and wellness, worldwide. Bioheart is the beginning of this journey." [Read the full article here.]( ----- BTCY Recap - The 5 Top Potential Breakout Catalysts To Know No. 1 - Zacks Small-Cap Research Provides $7.50 Price Target No. 2 - 2023 Sales Could Grow Significantly With Signing Of New Distribution Agreement No. 3 - A Massive Revenue Growth Announcement Highlights A Company On The Rise No. 4 - A Low Float Provides Volatility Potential On A Daily Basis No. 5 - Company's Device Added To Prestigious TIME Magazine List ----- Coverage is officially reinitiated on BTCY. When time permits, do this: Get BTCY on your radar now. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Ownership of FI has now moved to a single individual. Disclosure: I am not a lic-ensed fina-ncial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> [( An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates stockwirenews . com (“SWN”), and owns and operates stockstreetwire . com ("SSW"). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 9/15/21 and ending on 9/16/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. StockNewsWire LLC was paid sixty-seven thousand five hundred USD via bank wire transfer. StockWireNews owns zero shares of (BTCY). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 10/7/21 and ending on 10/8/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. StockNewsWire LLC was paid fifteen thousand USD via bank wire transfer. StockWireNews owns zero shares of (BTCY). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a one day period beginning on 10/29/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. StockNewsWire LLC was paid ten thousand USD via bank wire transfer. StockWireNews owns zero shares of (BTCY). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 12/27/21 and ending on 12/28/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. StockNewsWire LLC was paid twenty-five thousand USD via bank wire transfer. StockWireNews owns zero shares of (BTCY). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 1/24/22 and ending on 1/25/22 to publicly disseminate information about (BTCY) via Website, Email and SMS. StockNewsWire LLC was paid eighty-two thousand five hundred USD via bank wire transfer. StockWireNews owns zero shares of (BTCY). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 2/23/22 and ending on 2/24/22 to publicly disseminate information about (BTCY) via Website, Email and SMS. StockNewsWire LLC was paid eighty-two thousand five hundred USD via bank wire transfer. StockWireNews owns zero shares of (BTCY). Pursuant to an agreement between SWN Media LLC and Legends Media LLC, FierceInvestor (FI) has been hired for a period beginning on 10/27/22 and ending on 10/28/22 to publicly disseminate information about (BTCY) via Website, Email and SMS. SWN Media LLC was paid fifteen thousand USD via bank wire transfer. We own zero shares of (BTCY). To date we have been compensated a total of two hundred and fifteen thousand USD via bank wire transfer to disseminate information about (BTCY). Pursuant to an agreement between SWN Media LLC and Legends Media LLC, FierceInvestor (FI) has been hired for a period beginning on 11/20/22 and ending on 11/21/22 to publicly disseminate information about (BTCY) via Website, Email and SMS. SWN Media LLC was paid twenty-five thousand USD via bank wire transfer. We own zero shares of (BTCY). To date we have been compensated a total of two hundred and forty thousand USD via bank wire transfer to disseminate information about (BTCY). We have not been compensated for our 1/25/23 to 1/26/23 profile on (BTCY). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 11/08/2022 and ending on 11/21/2022 to publicly disseminate information about (BTCY:US) via digital communications. We have been paid an additional one hundred twelve thousand five hundred dollars USD via bank wire transfer. To date we have been paid five hundred eighty one thousand dollars USD via bank wire transfer to disseminate information about (BTCY:US) via digital communications. We own zero shares of (BTCY:US). [( Fierce | 539 W Commerce St, Dallas, TX 75208 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net